Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer

Perioperative and Palliative Chemotherapy for Esophageal Cancer

Perioperative and palliative chemotherapy for esophageal carcinoma has undergone substantial changes in recent years. The implementation of trastuzumab in the treatment of HER2-positive advanced adenocarcinoma is a milestone as it marked the introduction of the first molecularly targeted treatment of gastric cancer. Current studies are investigating whether anti-HER2-directed treatment also pro...

“Targeted” Chemotherapy for Esophageal Cancer

Citation: Abdo J, Agrawal DK and Mittal SK (2017) " Targeted " Chemotherapy for Esophageal Cancer. Due to its increasing incidence and low survival rate, esophageal cancer (EC) is now considered, even by non-medical professionals, as an extremely difficult cancer to beat akin to well-known terminal indications such as pancreatic and lung cancers. The average 5-year survival of EC is less than 1...

Palliative chemotherapy for recurrent and metastatic esophageal cancer.

More than two-thirds of patients diagnosed with esophageal cancer will have unresectable disease. The objective of this article is to review the clinical trials utilizing cytotoxic chemotherapy in patients with recurrent and metastatic esophageal cancer. A computerized (MEDLINE) search was performed to identify papers published on this topic between 1966 and 2007. A total of 96 trials were subs...

Combining chemotherapy and targeted therapies in metastatic colorectal cancer.

Colorectal cancer remains one of the major causes of cancer death worldwide. During the past years, the development of new effective treatment options has led to a considerable improvement in the outcome of this disease. The advent of agents such as capecitabine, irinotecan, oxaliplatin, erbitux and bevacizumab has translated into median survival times in the range of 2 years. Intense efforts h...

Esophageal Endoprosthesis by Laparo- Gastroscopy with Transtumoral Drilling – Palliative Therapeutic Option in Advanced Gastroesophageal Junction Adenocarcinoma